Presents a letter to the editor regarding an article previously published in the 'Journal of the American Medical Association' which discussed direct-to-consumer advertising (DTCA) and how drug companies should share product liability relating to advertising claims; How DTCA has the power to change patients' perspectives and personal risk-benefit analysis.